Over deze organisatie

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA and now has offices in a number of European countries including the Netherlands.

Lees meer

‘’I have never worked for a company where individual and team contributions are so frequently and openly shared, acknowledged and celebrated. This, plus the welcoming and collaborative attitude of all Alnylam-ites and the company’s can-do mentality has made this my favorite place to work!’’

Jessica Diez Canseco Quintana - Turfboer

Lees meer

Great Place to Work over

Alnylam meets the criteria of Great Place to Work. Based on the required minimum score on the Great Place to Work employee survey Alnylam is certified.

The employees score Alnylam the highest on Camaraderie and Pride. The statement ‘When I look at what we accomplish, I feel a sense of pride’ has a score of 100%.

Lees meer

At Alnylam we take a bold view of translating scientific research into a pipeline of new drugs. The positive and highly engaged culture of our team of people with different skills, experiences and backgrounds is key to bringing these medicines successfully to patients

Marco Fossatelli

Lees meer

Kun je de content niet zien? Accepteer de cookies om het zichtbaar te maken.